We previously reported in vitro synergistic activity combining a DGKα-inhibiting compound with radiation against GBM stem-like cells [37], and our unpublished data also suggest broad in vitro synergistic activity against GBM with combinations of a DGKα inhibitor and several classes of anti-tumor agents. The gene discussed is DGKA; the disease is glioblastoma.